Larvol Delta - First-Patient-Dosed-in-Phase-2-Portion-of-Aulos-Biosciences-Phase-12-Clinical-Trial-for-AU007-a-Computationally-Designed-IL2-Antibody-for-Solid-Tumor-Cancers

AU-007 - Aulos Biosci

https://www.businesswire.com/news/home/20240125588332/en/First-Patient-Dosed-in-Phase-2-Portion-of-Aulos-Bioscience%E2%80%99s-Phase-12-Clinical-Trial-for-AU-007-a-Computationally-Designed-IL-2-Antibody-for-Solid-Tumor-Cancers

Jan 25, 2024

SHARE THIS

Print
Email
More sharing

Reddit

StumbleUpon

Delicious

Prev Next